According to a report published in Cancer Epidemiology, Biomarkers, & Prevention, once women stop hormonal therapies, the proportion of women with breast cancer decreases, which supports the deterrence of hormones leading to tumor shrinkage. Assumptions.
As part of the National Breast Cancer Monitoring Association, researchers studied 741,681 long-term data (3.3 years on average per person) of 163,490 women aged 50 to 79. These women are health associations. Members and did not previously have a history of breast cancer.
"This is the first time that we have examined the relationship between hormonal therapy in women undergoing screening mammography studies and the diagnosis of breast cancer," said Diana S. M. Dr. Buist, senior researcher at the Group Health Institute said.
Previous studies have shown that a significant decline in new breast cancer may be due to a significant decline in the use of hormone therapy in people, through the use of screening mammography, since 2002, when the Women's Health Initiative published women using both estrogen and pregnancy. Ketones have a higher incidence of breast cancer than those who use placebo or estrogen alone. Some aspects have suggested that the reduction in the use of hormonal therapies may be the cause of the decrease in the incidence of breast cancer, possibly due to shrinkage of the tumor, Dr. Buist explained. But others have argued that the decline in breast cancer incidence and use of hormones may be due to the fact that early hormone users may have less attention to breast cancer or less to see a doctor. They may receive less screening than those who have never used hormones. Check the mammogram.
"We intend to test this view," Dr said. Buist said, “Our results seem to refute this view.†Prior to 2002, patients who received hormone therapy earlier had lower rates of screening mammography than those who used hormone therapy. "But we have found that this is no longer a fact," she said. In fact, patients who use hormonal therapy early have had the same or slightly higher proportion of screening mammography as current hormonal users. "We concluded that the difference in the proportion of screening mammograms does not explain the decline in the incidence of breast cancer in women who have stopped using hormone therapy," Dr. Buist said.
As part of the National Breast Cancer Monitoring Association, researchers studied 741,681 long-term data (3.3 years on average per person) of 163,490 women aged 50 to 79. These women are health associations. Members and did not previously have a history of breast cancer.
"This is the first time that we have examined the relationship between hormonal therapy in women undergoing screening mammography studies and the diagnosis of breast cancer," said Diana S. M. Dr. Buist, senior researcher at the Group Health Institute said.
Previous studies have shown that a significant decline in new breast cancer may be due to a significant decline in the use of hormone therapy in people, through the use of screening mammography, since 2002, when the Women's Health Initiative published women using both estrogen and pregnancy. Ketones have a higher incidence of breast cancer than those who use placebo or estrogen alone. Some aspects have suggested that the reduction in the use of hormonal therapies may be the cause of the decrease in the incidence of breast cancer, possibly due to shrinkage of the tumor, Dr. Buist explained. But others have argued that the decline in breast cancer incidence and use of hormones may be due to the fact that early hormone users may have less attention to breast cancer or less to see a doctor. They may receive less screening than those who have never used hormones. Check the mammogram.
"We intend to test this view," Dr said. Buist said, “Our results seem to refute this view.†Prior to 2002, patients who received hormone therapy earlier had lower rates of screening mammography than those who used hormone therapy. "But we have found that this is no longer a fact," she said. In fact, patients who use hormonal therapy early have had the same or slightly higher proportion of screening mammography as current hormonal users. "We concluded that the difference in the proportion of screening mammograms does not explain the decline in the incidence of breast cancer in women who have stopped using hormone therapy," Dr. Buist said.
JeeHTD is a professional machinery manufacturer with more than 12 years. We have experience in mask making machine market industry for more than 5 years. We offer professional after-sales service, such as installation instruction, training and machine repairing. To provide customers high quality products and high quality service is always our aim of work. We can be your reliable business partner!
Mask Making Machine,Face Mask Making Machine,Surgical Mask Making Machine,Medical mask machine
HTD INTERNATIONAL , https://www.jeehtd.com